Medizone files AsepticSure patent application
Medizone of San Francisco has submitted a patent application for its AsepticSure ozone-based sterilisation system, which is said to eliminate hospital-based bacterial pathogens. The patent covers disinfection of rooms and their contents within all healthcare facilities, as well as schools and government buildings.
The company says that following months of development and laboratory research, it has filed a ‘very solid’ patent application for its AsepticSure product.
Edwin Marshall, ceo of Medizone, said: "This is not just pumping ozone gas into a room. This patent filing not only identifies a number of unique technologies and their protocols, but also provides the scientific data proving our ability to obtain 4.4 log/99.994% to 5 log/99.999% kill rates for all of the pathogens of concern in hospital-acquired infections."
The company plans to start trials, including a hospital mock-up and then hospital beta testing of the production prototype, later this year. At its recently opened laboratory at Queen’s University, Kingston, Ontario, Medizone will work on gaining additional knowledge about the pathogens with which it has already had success, and other agents that might be commercially advantageous as it advances the application of AsepticSure beyond the hospital environment.
Initial sales are currently targeted to commence by the end of this year.
Contact {encode="operations@medizoneint.com" title="operations@medizoneint.com"} www.medizoneint.com